Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019026019) USE OF 3-METHYLMETHCATHINONE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention.

2. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 1, wherein said 3-MMC is administered prior to said psychotherapeutic intervention.

3. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 1, wherein said 3-MMC is administered during said psychotherapeutic intervention.

4. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 3, wherein said 3-MMC is administered at least twice during said psychotherapeutic intervention.

5. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 1, wherein said 3-MMC is administered after said psychotherapeutic intervention.

6. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of any one of claims 1-5, wherein said 3-MMC is administered to said subject in an amount of approximately 50 mg to approximately 500 mg per therapeutic intervention.

7. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 6, wherein said 3-MMC is administered to said subject in an amount of approximately 100 mg to approximately 400 mg per therapeutic intervention.

8. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 6, wherein said 3-MMC is administered to said subject in an amount of approximately 100 mg to approximately 200 mg per therapeutic intervention.

9. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of any one of claims 1-8, wherein said 3-MMC is administered to said subject in an amount of approximately 100 mg or 200 mg per therapeutic intervention.

10. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of any one of claims 1-9, wherein said psychotherapeutic intervention is for distress of said subject.

11. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 10, wherein said treating is for reducing said distress in said subject.

12. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 10 or 11, wherein said distress is selected from the group consisting of cognitive, emotional, behavioral, relationship and spiritual distress.

13. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of any one of claims 10-12, wherein said distress is a condition or disorder selected from the group consisting of personal history of psychological trauma, parent-child relational problem, personal history (past history) of neglect in childhood, personal history (past history) of physical abuse in childhood, personal history (past history) of psychological abuse in childhood, personal history (past history) of sexual abuse in childhood, personal history (past history) of spouse or partner neglect, personal history (past history) of spouse or partner psychological abuse, personal history (past history) of spouse or partner physical violence, personal history (past history) of spouse or partner sexual violence, phase of life problem, relationship distress with spouse or intimate partner, stimulant use disorder and posttraumatic stress disorder.

14. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of any one of claims 10-12, wherein said subject is diagnosed with a stress- sensitive disorder selected from the group consisting of Post-traumatic Stress Disorder (PTSD), Bipolar Disorder, Acute Stress Disorder, anxiety disorders such as Generalized Anxiety Disorder, Obsessive-Compulsive Disorder, social anxiety disorders, Panic Disorders, phobias, obsessive compulsive disorders, and Trichotillomania.

15. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of any one of claims 1-14, wherein said psychotherapeutic intervention is selected from the group consisting of psychoanalytic and psychodynamic therapy, behavioral therapy, cognitive therapy, humanistic therapy and integrative or holistic therapy.

16. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 15, wherein said psychotherapeutic intervention is humanistic therapy or integrative/holistic therapy.

17. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 10, wherein reducing said distress comprises at least one of the following: improving stability in the work/home environment, improving behaviors, improving employment functioning, improving vocational functioning, reducing cognitive stress, reducing emotional stress, improving the subject's living situation, improving the subject's family relationships, improving social relationships, improving the subject's sense of meaning to life, improving the subject's sense of purpose to life, reducing mental health symptoms, reducing addiction behaviors and reducing chemical dependencies.

18. The 3-methylmethcathinone (3-MMC) for treating a subject undergoing a psychotherapeutic intervention of claim 10, wherein reducing said distress comprises reducing the number and/or frequency of psychotherapeutic interventions, and/or reducing addiction behaviors and reducing chemical dependencies.

19. A kit for use in treating a subject undergoing a psychotherapeutic intervention comprising a therapeutically effective amount of 3-methylmethcathinone (3-MMC) and instructions for the use of 3-MMC in conjunction with said psychotherapeutic intervention.

20. The kit of claim 19, wherein said psychotherapeutic intervention is for distress in said subject.

21. The kit of claim 19 or 20, wherein said psychotherapeutic intervention is selected from the group consisting of psychoanalytic and psychodynamic therapy, behavioral therapy, cognitive therapy, humanistic therapy and integrative or holistic therapy.